Woodline Partners LP Increases Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Woodline Partners LP raised its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,120,922 shares of the company’s stock after buying an additional 16,977 shares during the period. Vaxcyte comprises about 0.6% of Woodline Partners LP’s investment portfolio, making the stock its 20th biggest holding. Woodline Partners LP owned approximately 0.90% of Vaxcyte worth $91,759,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Soleus Capital Management L.P. boosted its position in Vaxcyte by 266.2% during the 4th quarter. Soleus Capital Management L.P. now owns 99,050 shares of the company’s stock valued at $8,108,000 after buying an additional 72,000 shares during the period. Twinbeech Capital LP purchased a new stake in Vaxcyte during the 4th quarter valued at $22,916,000. Toronto Dominion Bank purchased a new stake in Vaxcyte during the 4th quarter valued at $900,000. Scientech Research LLC boosted its position in Vaxcyte by 18.5% during the 4th quarter. Scientech Research LLC now owns 15,273 shares of the company’s stock valued at $1,250,000 after buying an additional 2,385 shares during the period. Finally, Rafferty Asset Management LLC boosted its position in Vaxcyte by 128.6% during the 4th quarter. Rafferty Asset Management LLC now owns 147,436 shares of the company’s stock valued at $12,069,000 after buying an additional 82,940 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of several analyst reports. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Guggenheim reissued a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Cantor Fitzgerald started coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an “overweight” rating for the company. Finally, The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Price Performance

Shares of PCVX opened at $32.03 on Tuesday. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company has a 50-day simple moving average of $41.73 and a two-hundred day simple moving average of $70.94. The firm has a market capitalization of $4.13 billion, a PE ratio of -6.96 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the firm posted ($0.85) EPS. Analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.